^
Association details:
| Biomarker: | MYC translocation + BCL2 translocation |
|---|---|
| Cancer: | Lymphoma |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2936 Prospective Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas
Published date:
11/03/2022
Excerpt:
Adult patients with newly diagnosed DLBCL (stage II-IV) with dual MYC and BCL2 translocations (DHL)...The ORR after LEN and DA-EPOCH-R induction was 49/54 (90.7%) with CR of 46/54 (85.2%)….LEN with DA-EPOCH-R for patients with DEL and DHL has a high response rate, encouraging survival, and met the primary endpoint for PFS.
Secondary therapy:
EPOCH-R
DOI:
https://doi.org/10.1182/blood-2022-168444
Trial ID:
